10x GenomicsvsUnitedHealth

TXG and UNH stock compared: price, dividend, valuation and results, from SEC filings.

TXG

10x Genomics, Inc.

$60.14

Value $7.7B

+5.40%
TXG's page

UNH

UnitedHealth Group Incorporated

$326.54

Value $296B

-6.88%
UNH's page

10x Genomics (TXG) has a market value of $7.7B and UnitedHealth (UNH) $296B. Over the last year, with dividends, TXG moved +286.6% and UNH +6.9%. Dividend yield: TXG none, UNH 2.77%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TXG$7.7B

    UNH$296B

    UNH is 39 times TXG

  • Revenue, 12 months

    TXG$619M

    UNH$450B

    UNH is 727 times TXG

  • Net income, 12 months

    TXG-$67M

    UNH$15.9B

  • Operating margin

    TXG-11.7%

    UNH5.3%

    17.0 points apart

  • ROIC

    TXG-7.0%

    UNH11.3%

    18.3 points apart

  • P/E

    TXG–

    UNH18.7

  • Dividend yield

    TXG0.0%

    UNH2.8%

    2.8 points apart

  • 5-year return

    TXG-59.8%

    UNH-20.5%

    39.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TXG-59.8%

UNH-20.5%

05010015020222023202420252026
Returns by period
PeriodTXGWith dividendsUNHWith dividends
1 year since November 18, 2025+286.6%Price +286.6%+6.9%Price +4.1%
3 years since November 17, 2023+42.6%+12.6% a yearPrice +42.6%-35.2%-13.4% a yearPrice -39.1%
5 years since November 18, 2021-59.8%-16.7% a yearPrice -59.8%-20.5%-4.5% a yearPrice -27.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TXG10x GenomicsUNHUnitedHealth

Valuation

TXGUNH
Valuation
Price$60.14$326.54
Market value$7.7B$296B
Enterprise value (EV)$7.1B$342B
P/E–18.7
P/E, 5-year median–25.0
P/B9.22.9
EV/EBIT–14.3
Free cash flow yield1.2%7.7%

Results and growth

TXGUNH
Results and growth
Revenue, 12 months$619M$450B
Net income, 12 months-$67M$15.9B
Free cash flow, 12 months$94M$22.8B
Earnings per share, 12 months-$0.52$17.52
Revenue growth, year on year5.3%11.8%
Revenue growth a year, past+16.6%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

TXGUNH
Margins and returns on capital
Gross margin71.9%88.3%
Operating margin-11.7%5.3%
Net margin-10.8%3.5%
ROIC-7.0%11.3%
ROE-8.3%15.5%

Balance sheet

TXGUNH
Balance sheet
Cash$576M$28.5B
Total debt$76M$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

TXGUNH
Dividends and buybacks
Dividend yield–2.8%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.9%
Shareholder yield–4.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TXG or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, 10x Genomics or UnitedHealth?

By market value, UnitedHealth ($296B) is about 38.6 times 10x Genomics ($7.7B), at today's prices.

How did TXG and UNH stock do over the last 5 years?

Since November 18, 2021, TXG's price moved -59.8% and UNH's -27.4%. With dividends: TXG -59.8% (-16.7% a year), UNH -20.5% (-4.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, TXG or UNH?

The dividend yield at today's price is none for 10x Genomics and 2.77% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, 10x Genomics or UnitedHealth?

Over the last twelve months, the net margin was -10.8% for 10x Genomics and 3.5% for UnitedHealth, and the operating margin -11.7% and 5.3%. Revenue was $619M and $450B.

Which is the better investment, 10x Genomics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.